Primus In News
Novartis Vymada patent revoked, generics set to slash prices by 70%
17-09-2025
Nilaya Varma, Co-founder and Group CEO, Primus Partners, highlighted that Vymada holds a significant presence in India, with annual sales of around ₹550 crore. The Indian Patent Office’s decision to revoke Novartis’ patent, citing lack of novelty and technical advancement, is set to reshape the ₹550 crore market. This move is expected to open the floodgates for generics, potentially reducing prices by over 70% and improving access for millions of cardiovascular patients across the country.
Explore Related Insights
- CFOs say RBI 40 bps rate hike crucial to contain inflation, dont expect major impact on demand
- Zoho joins India's Inc in semiconductor diversification: Here's why
- Unleashing potential: the vibrant landscape of innovation and entrepreneurship in India's tier 2 and tier 3 cities
- Primus Partners unveils roadmap to boost India’s textile exports to $100 billion by 2030
